3.115  -0.085 (-2.66%)		08-18 14:14
Open: 3.2 High: 3.2 Volume: 58,476		Pre. Close: 3.2 Low: 3.09 Market Cap: 21(M)

Short term
Mid term
Targets	6-month :	4.44	1-year :	5.03
Resists	First :	3.8	Second :	4.3
Pivot price	3.68
Supports	First :	3	Second :	2.49
MAs	MA(5) :	3.47	MA(20) :	3.71
	MA(100) :	4.89	MA(250) :	8.99
MACD	MACD :	-0.2	Signal :	-0.2
%K %D	K(14,3) :	22.9	D(3) :	33.8
RSI	RSI(14): 29.2
52-week	High :	23.5	Low :	2.9

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CNSY ] has closed below the lower bollinger band by 10.3%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ CNSY ] is to continue within current trading range. It is unclear right now based on current values. 55.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 31 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	3.51 - 3.53	3.53 - 3.55
Low:	2.95 - 2.97	2.97 - 2.99
Close:	3.16 - 3.2	3.2 - 3.24

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.

Mon, 17 Aug 2026
symbol__ Stock Quote Price and Forecast - CNN

Mon, 17 Aug 2026
Cerenome (CNSY) Q2 Earnings Miss; Price-to-Sales Valuation Signa - GuruFocus

Sun, 16 Aug 2026
Book value per share of Cerenome, Inc. – NASDAQ:CNSY - TradingView

Sun, 16 Aug 2026
Cerenome (CNSY) Stock Analysis Report | Financials & Insights - Benzinga

Fri, 14 Aug 2026
Cerenome (CNSY) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance

Fri, 14 Aug 2026
Is Cerenome Inc (CNSY) Facing Increased Risks After Q2 Losses? E - GuruFocus

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Shares Out	7 (M)
Shares Float	6 (M)
Held by Insiders	1.8 (%)
Held by Institutions	14.9 (%)
Shares Short	709 (K)
Shares Short P.Month	1,120 (K)

EPS	21.55
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.74
Profit Margin	-230.3 %
Operating Margin	-692.6 %
Return on Assets (ttm)	-73.9 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	-3 %
Gross Profit (p.s.)	-0.63
Sales Per Share	0.75
EBITDA (p.s.)	-2.69
Qtrly Earnings Growth	0 %
Operating Cash Flow	-21 (M)
Levered Free Cash Flow	-15 (M)

PE Ratio	0.14
PEG Ratio	2.4
Price to Book value	1.78
Price to Sales	4.13
Price to Cash Flow	-1.03

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.